Not medical advice. Talk to your provider before using any peptide. Full disclaimer
GHRP-2
Beginner tier: 100 mcg, daily · community consensus
Also known as: pralmorelin, GHRP Kaken 100, KP-102
A 38% drop in GH response after just five days of continuous use. That single data point from Nijland et al. [1] tells you everything about GHRP-2: it hits hard and fast, but the pituitary adapts quickly. GHRP-2 (pralmorelin) is a synthetic hexapeptide that binds GHS-R1a, the ghrelin receptor, to trigger a potent growth hormone pulse. Japan approved it in 2004 as a one-time diagnostic agent for GH deficiency testing. No therapeutic approval exists anywhere. Athletes and anti-aging users favor it for a strong per-injection GH spike, paired with a GHRH peptide and strict cycling to outrun desensitization.
What Is GHRP-2?
A 38% decline in peak GH response from day one to day five. That finding comes from Nijland and colleagues (Eur J Endocrinol 1998), who dosed nine healthy young men at 100 mcg/day subcutaneous [1]. It shaped how experienced users run GHRP-2 today.
GHRP-2, also called pralmorelin (CAS 158861-67-7), is a synthetic hexapeptide growth hormone secretagogue. It binds GHS-R1a on pituitary somatotrophs, mimicking ghrelin to trigger a rapid, dose-dependent GH pulse. Compared to GHRP-6, it reached half its maximal GH effect at a lower dose in a swine study (Raun 1998). Community reports describe less appetite stimulation, though a human study found GHRP-2 raised food intake 35.9% [4]. In the same swine study, GHRP-2 worked at a lower dose than ipamorelin, but ipamorelin reached the higher GH peak [7]. GHRP-2 also raised ACTH and cortisol in those swine, and ipamorelin did not. No human study has compared the two.
The practical community protocol runs 100 to 200 mcg subcutaneous two to three times daily on an empty stomach, co-injected with CJC-1295 (no DAC) for complementary GHRH + GHRP stimulation. That combination produces two to three times the GH pulse of either peptide alone, according to consistent user reports across hundreds of Reddit threads. Cycling is mandatory: 5 days on, 2 days off within each week, plus 8 weeks on, 4 weeks off for the gross cycle.
Japan's PMDA approved GHRP-2 (brand name GHRP Kaken 100) in 2004 as a single-dose IV diagnostic agent for GH deficiency. No country has approved it therapeutically. Over 200 PubMed papers cover its pharmacology, but most are mechanistic or short-term. No long-term therapeutic RCT exists for the doses the community uses. The evidence base is strong on mechanism and acute pharmacology; it's thin on multi-month safety at 100 to 300 mcg SC daily.
How GHRP-2 Works
GHRP-2 (pralmorelin) binds the growth hormone secretagogue receptor GHS-R1a, a G-protein coupled receptor on pituitary somatotrophs and hypothalamic neurons. GHS-R1a is the same receptor that ghrelin, the endogenous hunger hormone, activates.
Binding triggers phospholipase C and protein kinase C signaling. That depolarizes somatotrophs and opens voltage-gated calcium channels, producing a rapid GH pulse within 15 to 30 minutes of injection. The mechanism also works upstream: GHRP-2 stimulates hypothalamic GHRH neurons and suppresses somatostatin tone, creating a dual push-pull effect on GH release.
The cortisol and prolactin elevation users notice comes from partial activation of ACTH-releasing pathways at the pituitary. Arvat et al. confirmed this is transient, returning to baseline within two to three hours post-injection [2]. Hexarelin at equal doses raised these hormones by similar amounts in the same study; head-to-head human data against GHRP-6 are lacking.
One pharmacological detail matters for protocol design. GHS-R1a undergoes beta-arrestin-mediated receptor internalization with chronic agonist exposure. That is the molecular basis for the 38% GH attenuation Nijland documented over five daily doses [1]. Receptor density recovers during off periods, which is why the 5-on/2-off weekly schedule preserves response. The elimination half-life is short (0.55 hours per Pihoker et al. Phase I pediatric PK)[3], so the compound clears quickly once injections stop.
GHRP-2 Benefits
- GHRP-2 benefits center on potent GH release and the downstream effects of raised growth hormone signaling.
- Of the three GHRPs Bowers' group first tested in people, GHRP-2 released GH most effectively [6]. Hexarelin matched it at equal IV doses [2][8]. Head-to-head community comparisons consistently rank GHRP-2 above ipamorelin for raw GH output.
- Complementary with CJC-1295 (no DAC): co-injection produces two to three times the GH pulse of either alone by activating dual pituitary pathways (GHRHR + GHS-R1a simultaneously).
- Moderate appetite stimulation that supports lean bulking. The ghrelin-mimetic hunger effect is real but manageable, less extreme than GHRP-6. Users on caloric surplus protocols consider this a feature.
- Improved deep sleep reported within the first week of bedtime dosing. GH promotes slow-wave sleep architecture; community reports of vivid dreams and better recovery are consistent across hundreds of threads on r/Peptides.
- One of the most studied GHRPs in the literature (200+ PubMed papers). The GHS-R1a binding mechanism, acute GH kinetics, and side effect profile are well characterized, not extrapolated from animal models alone.
- Body composition shifts visible by months two to three: reduced abdominal fat, improved muscle fullness, and faster connective tissue recovery per consistent user timelines.
GHRP-2: Science vs Community Consensus
Well-studied second-generation GHRP.
Read the evidence (key study, limitations)
GHS-R1a binding mechanism and acute GH pulse confirmed across multiple human studies. Approved in Japan as a single-dose diagnostic agent (100 mcg IV, 2004 PMDA). No therapeutic RCT exists for the bodybuilding/anti-aging dosing range (100-300 mcg SC 2-3× daily). Published data documents rapid receptor desensitization: 38% GH attenuation from day 1 to day 5 at 100 mcg/day SC [1]. Mild, transient cortisol and prolactin elevation confirmed [2]. 200+ PubMed papers; most are mechanistic or short-term pharmacological studies, not therapeutic trials.
Nijland et al. 1998 (PMID 9820615): peak GH 83 to 51 µg/L (about 38% attenuation) day 1→5, 100 mcg/day SC in 9 healthy young men; strongest clinical basis for cycling requirement. Pihoker et al. 1998 (PMID 9543135): Phase I pediatric PK; elimination t½ = 0.55 ± 0.14 h (IV). Arvat et al. 1997 (PMID 9285939): confirmed transient cortisol/prolactin elevation, returning to baseline by 2-3h.
No long-term therapeutic RCT. Japan approval limited to single-dose IV diagnostic use. SC bioavailability not formally established in humans. Rapid desensitization limits continuous use. No human data on multi-month SC dosing safety.
Effective and reliable GHRP with a strong GH pulse, but losing market share to ipamorelin due to cortisol/prolactin side effects and faster desensitization.
Read the reports (what users report 5, common issues 5)
Preferred when maximum GH output per injection is the goal. Users call it the "middle ground" GHRP: cleaner than GHRP-6 (less hunger) and stronger than ipamorelin (a larger GH spike). No human study has tested that ranking; in swine, GHRP-2 worked at a lower dose, but ipamorelin reached the higher GH peak [7]. Near-universally stacked with CJC-1295 (no DAC) or Sermorelin for a combined GHRH + GHRP GH pulse.
- Strong, reliable GH pulse: users rate it stronger than ipamorelin per injection (no human comparison exists; in swine, ipamorelin peaked higher, PMID 9849822)
- Paired with CJC-1295 (no DAC) for a larger GH pulse than either alone (community reports)
- Moderate appetite increase useful for lean bulking (less extreme than GHRP-6)
- Improved deep sleep and recovery within weeks 1-2
- Well-documented mechanism: one of the most-studied GHRPs in PubMed
- Rapid receptor desensitization: GH pulse declines ~38% in 5 days of continuous use
- Cortisol and prolactin elevation: mild but undesirable for long-term hormone optimization
- Hunger side effect: inconvenient for cutting protocols
- Strict fasting window required: food raises somatostatin and blunts GH response
- Popularity declining vs. ipamorelin among community users seeking cleaner hormonal profile
Science and community agree on the GHS-R1a mechanism, acute GH pulse, and cortisol/prolactin side effects. Desensitization is clinically documented (PMID 9820615) and community has independently converged on 5-on/2-off cycling: strong alignment on this point. Community SC dosing (100-200 mcg 2-3× daily) is not supported by any therapeutic RCT; it is extrapolated from the Japan diagnostic dose and short-term research studies. Cycling rationale is science-supported in principle, but the 8-week on / 4-week off ratio is community convention, not a clinical protocol. Community reports rank GHRP-2's GH pulse above ipamorelin's. In swine, potency favored GHRP-2 and peak GH favored ipamorelin (PMID 9849822). The two have not been compared in people.
GHRP-2 Dosage Guide
Reconstitution math for the standard 5 mg vial: add 2 mL bacteriostatic water. That gives you 2,500 mcg/mL. On a U-100 insulin syringe, 100 mcg equals 4 units. A 200 mcg dose is 8 units. One vial at 200 mcg twice daily lasts about 12.5 days.
The fasting window is non-negotiable. Food raises somatostatin, which directly blunts the GH pulse. No food for 30 minutes before or after injection. Most beginners who report "GHRP-2 doesn't work" are eating too close to their injection.
Stack it. Running GHRP-2 alone leaves GH output on the table. Co-inject with CJC-1295 (no DAC) at 100 mcg for the complementary pulse. Same syringe, same injection, same time.
Store reconstituted vials refrigerated at 2 to 8 degrees Celsius and use within four weeks. Don't freeze reconstituted solution. Lyophilized powder is stable refrigerated for up to 12 months.
The 5-on/2-off schedule is the one thing experienced users universally agree on. Start it from week one, not after you notice declining response.
Cycling Protocol
Continuous use may reduce GH response over time due to receptor desensitization. Cycle 8 weeks on, 4 weeks off. Some users run 5 days on, 2 days off within each cycle week to preserve sensitivity.
GHRP-2 produces the fastest-documented receptor desensitization of commonly used GHRPs: 38% GH pulse attenuation from day 1 to day 5 of 100 mcg/day SC dosing in healthy men (PMID 9820615). This is caused by GHS-R1a downregulation and β-arrestin-mediated receptor internalization with chronic agonist exposure. The 5-day attenuation curve is the primary rationale for the within-week 5-on/2-off schedule used by experienced community members. The 8-week on / 4-week off gross cycle is a community convention, not clinically validated, but consistent with the principle of allowing receptor recycling. Antibody formation has been reported with long-term use of some GHRPs but is not the primary desensitization mechanism here.
- GH pulse response weakening: reduced post-injection warmth/tingling that was present in early weeks
- Sleep improvement effect diminishing after weeks 3-4 of continuous dosing
- IGF-1 levels plateauing or declining despite continued fasted protocol
- Appetite stimulation diminishing (hunger spike post-injection becomes less pronounced)
Or use the universal Peptide Calculator for any peptide.
GHRP-2 Protocols by Goal
Expected: Improved sleep depth within weeks 1-2; mild recovery improvement by weeks 3-4; modest body composition changes (reduced abdominal fat, improved muscle fullness) by months 2-3
Monitor: Baseline IGF-1 before starting; recheck at week 4 and week 8. Fasting glucose at baseline.
How to Use GHRP-2
- 1Reconstitute a 5 mg vial with 2 mL bacteriostatic water
Aim the stream at the glass wall, not directly into the powder. Let it dissolve; don't shake. This gives you 2,500 mcg/mL.
- 2Step 2
Draw your dose into a U-100 insulin syringe (29 or 31 gauge, half-inch needle). For 100 mcg, draw to the 4-unit mark. For 200 mcg, draw to the 8-unit mark. For 300 mcg, draw to the 12-unit mark.
- 3Clean the injection site with an alcohol swab
Pinch skin at the abdomen, thigh, or upper arm. Insert at a 45-degree angle and inject slowly.
- 4Inject on an empty stomach
Minimum 30 minutes fasted before and 30 minutes fasted after. Food raises somatostatin and kills the GH pulse.
- 5Step 5
Best timing is before bed (to amplify the natural nocturnal GH surge) or first thing in the morning fasted. For twice-daily protocols, do both. For three times daily, add a post-workout injection (minimum 20 minutes after exercise, still fasted, at least 3 hours between injections).
- 6Step 6
If stacking with CJC-1295 (no DAC), draw 100 mcg of CJC into the same syringe before drawing your GHRP-2 dose. One injection covers both.
- 7Rotate injection sites each time
Refrigerate the reconstituted vial between uses.
Alternative Routes
100 mcg IV single bolus (Japan PMDA approved diagnostic dose)
IV is the only clinically validated administration route for pralmorelin. Japan diagnostic protocol: 100 mcg IV bolus for GH deficiency testing (GH stimulation test). Half-life 33 min IV. Not appropriate for repeated self-administration.
PMID 9390009 studied intranasal GHRP-2 in children with short stature; systemic bioavailability via intranasal route significantly lower than SC
Studied in pediatric short stature context only. Bioavailability substantially lower than SC. Community does not use this route; no practical dosing conversion validated.
GHRP-2 Stacking Protocols
Works With
Primary and near-universal stack. GHRH (CJC-1295 no DAC) + GHRP (GHRP-2) activates dual pituitary pathways, GHRHR + GHS-R1a; community reports describe a larger GH pulse than either alone. Co-injected simultaneously so both signals hit the same pulse window.
100 mcg CJC-1295 (no DAC) + 100-200 mcg GHRP-2 SC, 2-3× daily, fasted
Lower-cost alternative GHRH for the GHRP-2 stack. Shorter half-life than CJC-1295 (no DAC), otherwise the same added boost via GHRHR activation. Preferred by users seeking lower cost or softer GH stimulus.
100-300 mcg Sermorelin + 100-200 mcg GHRP-2 SC, 2× daily, fasted
Concurrent tissue repair stack (separate mechanism, not GH pathway). GH elevation from GHRP-2 complements BPC-157 angiogenic and healing signaling for injury recovery and connective tissue repair protocols.
Systemic recovery stack. TB-500 actin-binding and cell migration support + GH-mediated anabolic signaling combined in injury and post-surgery protocols.
Avoid
Both GHRP-2 and ipamorelin bind the same GHS-R1a receptor. Stacking two GHRPs at the same receptor provides no additive GH benefit and accelerates receptor desensitization. Choose one GHRP and pair it with a GHRH peptide instead.
Same GHS-R1a receptor as GHRP-2. At equal doses, hexarelin and GHRP-2 raise cortisol and prolactin by similar amounts (PMID 9285939). Combining them compounds these side effects with no documented GH benefit from dual GHS-R1a stimulation.
Do not combineSame GHS-R1a receptor. Stacking GHRP-2 + GHRP-6 is redundant. GHRP-6 adds dramatically more hunger stimulation and cortisol burden without additive GH benefit over a single GHRP.
Do not combineCombining GH secretagogues with exogenous recombinant HGH saturates the GH/IGF-1 axis and suppresses endogenous pulsatility. Eliminates the primary rationale for secretagogue use (axis preservation). Dramatically increases IGF-1 overshoot risk.
Do not combineEstimated Cost
Pricing updated 2026-04-09
GHRP-2 Side Effects
Receptor desensitization is the most clinically documented concern. Nijland et al. (1998) tracked peak GH falling from 83 to 51 µg/L, about 38%, from day one to day five at 100 mcg/day subcutaneous in nine healthy young men [1]. This is not a theoretical risk; it's measured and reproducible. Without cycling (5 days on, 2 days off minimum), the peptide loses a third of its effectiveness within a week. Users who skip cycling waste product and lose the GH output they're paying for.
Cortisol elevation is real but transient. Arvat et al. [2] documented mild ACTH and cortisol spikes post-injection that return to baseline within two to three hours. At standard doses (100 to 200 mcg once or twice daily), this rarely causes symptoms. Long-term cortisol data for GHRP-2 itself are lacking. In adults on hexarelin, a related GHRP, 16 weeks of twice-daily injections lowered the cortisol response [5]. Their prolactin response did not change. On three times daily advanced protocols, watch for disrupted sleep, irritability, or stubborn fat gain around the midsection. Get an AM cortisol lab at week eight if running the advanced protocol.
Prolactin elevation follows a similar pattern: mild, transient, dose-dependent. Symptomatic hyperprolactinemia (libido changes, gynecomastia) is uncommon at standard doses but warrants lab work if symptoms appear. The prolactin burden is similar to hexarelin's at equal doses [2] but higher than ipamorelin's.
Appetite increase hits 20 to 30 minutes after injection. GHRP-2 mimics ghrelin at GHS-R1a, and ghrelin is the hunger hormone. The effect is significantly less intense than GHRP-6 but more pronounced than ipamorelin. For cutting protocols, this can be disruptive. Shifting the bedtime dose to three or more hours after dinner (still fasted) helps manage it.
Water retention and mild edema are GH-class effects, not specific to GHRP-2. Expect some puffiness in the first two to four weeks that stabilizes.
Injection-site reactions include transient tingling and dizziness lasting 5 to 15 minutes post-injection. These are common, benign, and tend to diminish over the first week.
Carpal tunnel symptoms (hand tingling, grip weakness) signal excessive GH-mediated fluid retention. Reduce dose or frequency immediately. If symptoms persist beyond one week at a lower dose, discontinue for a minimum of four weeks.
GH antagonizes insulin action, and GHRP-2's cortisol co-elevation compounds this effect. Monitor fasting glucose at baseline and at weeks four and eight. Pre-diabetic individuals should check weekly. A fasting glucose above 125 mg/dL warrants dose reduction and medical review.
Contraindications: active cancer or history of malignancy (GH promotes cell proliferation), uncontrolled diabetes or diabetic retinopathy, pregnancy or breastfeeding, active pituitary tumors, and known hypersensitivity to pralmorelin. No human data exists on multi-month subcutaneous dosing safety at the doses the community uses.
Common Issues & Solutions
No IGF-1 change after 4-6 weeks: Most common cause is eating within 30 minutes before/after injection: food raises somatostatin and completely blunts the GH pulse. Check fasting compliance before questioning product quality.
GH response decreasing week over week: Rapid GHS-R1a desensitization is documented in 5 days of continuous daily use [1]. Immediately implement 5-on/2-off schedule within each week; consider a full 2-week break to restore receptor sensitivity.
Intense hunger within 20-30 minutes of injection: Expected ghrelin-mimetic effect. If hunger interferes with fasting compliance, shift bedtime dose later (post-dinner, 3+ hours fasted). GHRP-2 hunger is significantly less than GHRP-6 but more than ipamorelin.
Tingling, numbness, or grip weakness in hands: Early carpal tunnel symptom from GH-mediated fluid retention. Reduce dose or injection frequency immediately. If symptoms persist >1 week at lower dose, discontinue and allow 4+ weeks for GH-related edema to resolve.
Cortisol symptoms (poor sleep, irritability, fat gain despite protocol): GHRP-2 causes mild transient cortisol elevation: returns to baseline ~2-3h post-injection [2]. If symptoms persist, check AM cortisol lab. Switch to ipamorelin if cortisol sensitivity is a concern.
Ask AI about this page
Ask AI for a second opinion on GHRP-2 dosing and side effects
Contraindications
- Active cancer or history of malignancy: GH promotes cell proliferation
- Uncontrolled diabetes mellitus or diabetic retinopathy: GH antagonizes insulin and may worsen glycemic control
- Pregnancy or breastfeeding: effects on fetal development not established
- Active pituitary tumors or intracranial neoplasms
- Known hypersensitivity to GHRP-2 (pralmorelin) or any excipients
Drug Interactions
- Insulin and oral hypoglycemics: GH release antagonizes insulin action; blood glucose monitoring required
- Corticosteroids: chronic use may blunt GH response and reduce GHRP-2 efficacy
- Other GH secretagogues (GHRP-6, hexarelin, ipamorelin): additive GH release increases risk of side effects; avoid stacking without medical guidance
- Thyroid hormones: GH can accelerate T4-to-T3 conversion; monitor thyroid function during use
- Somatostatin analogs (octreotide, lanreotide): directly inhibit GH release, counteracting GHRP-2 effects
- Both GHRP-2 and ipamorelin bind the same GHS-R1a receptor. Stacking two GHRPs at the same receptor provides no additive GH benefit and accelerates receptor desensitization. Choose one GHRP and pair it with a GHRH peptide instead.
- Same GHS-R1a receptor as GHRP-2. At equal doses, hexarelin and GHRP-2 raise cortisol and prolactin by similar amounts (PMID 9285939). Combining them compounds these side effects with no documented GH benefit from dual GHS-R1a stimulation.
- Same GHS-R1a receptor. Stacking GHRP-2 + GHRP-6 is redundant. GHRP-6 adds dramatically more hunger stimulation and cortisol burden without additive GH benefit over a single GHRP.
Product Quality
GHRP-2 is among the more affordable GH secretagogues (~$28-$46 per 5mg vial), and budget products have variable quality standards. No GMP requirement applies to "research use only" peptide products. The peptide is a hexapeptide (MW ~817 Da): synthesis is straightforward and impurity profiles vary from product to product. Reconstituted peptide degrades faster than lyophilized powder; improper storage (not refrigerated, exposed to light) significantly reduces potency. No systematic product testing data for GHRP-2 specifically comparable to the Finnrick Analytics CJC-1295 dataset, but general research peptide quality concerns apply.
- A credible CoA is batch-specific and comes from a named third-party analytical lab (HPLC purity + MS identity confirmation); generic in-house documents prove little
- Store lyophilized powder at 2-8°C; refrigerate reconstituted solution and use within 4 weeks
- If IGF-1 is not moving after 4-6 weeks of strict fasting compliance and correct reconstitution, suspect underdosed or degraded product before increasing dose
- Price as a signal: 5mg vials typically run $28-$46 USD; significantly cheaper pricing suggests quality compromise
- Verify reconstitution calculation: 5mg vial + 2mL BAC water = 2,500 mcg/mL; 100 mcg = 4 units on a U-100 insulin syringe
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| IGF-1 | Baseline before starting; repeat at week 4 and week 8 | Age-adjusted normal range (not supraphysiological). Flag if above upper limit of normal. |
| Fasting glucose | Baseline; repeat at week 4 and week 8; weekly if pre-diabetic | <100 mg/dL (normal); 100-125 mg/dL warrants dose reduction and closer monitoring |
| Prolactin | Baseline; repeat at week 8 if symptoms emerge (libido changes, gynecomastia) | Normal laboratory reference range |
| AM cortisol | Baseline; repeat at week 8 if symptoms of cortisol excess emerge | Normal AM cortisol range (roughly 10-20 mcg/dL AM) |
| Thyroid (TSH, fT3, fT4) | Baseline; repeat at week 12 if symptoms emerge | Not listed |
Primary efficacy marker for sustained GH axis activation. Confirms peptide quality and dosing adequacy. Detects over-response requiring dose/frequency reduction.
GH release antagonizes insulin action. GHRP-2 causes cortisol co-elevation which further impairs glucose tolerance. Essential monitoring in individuals with any insulin resistance.
GHRP-2 causes mild transient prolactin elevation (confirmed PMID 9285939). Returns to baseline within 2-3h post-injection. Symptomatic hyperprolactinemia is uncommon at standard doses but warrants investigation at higher frequencies.
GHRP-2 transiently elevates cortisol/ACTH via pituitary ACTH-releasing pathway. Long-term data for GHRP-2 are lacking; in adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859).
GH accelerates T4-to-T3 conversion. Untreated hypothyroidism blunts GH response; GH supplementation can unmask subclinical hypothyroidism.
GHRP-2 Before and After
Improved sleep depth and recovery. Moderate appetite increase becomes noticeable. Mild water retention may occur as GH pulses elevate.
Recovery between training sessions improves. Skin quality begins to improve. Energy levels and mood stabilize. GH-mediated fat oxidation starts.
Body composition shifts become visible: reduced abdominal fat, improved muscle fullness. Joint and connective tissue feel better.
Peak benefits for body composition and recovery. Hair and nail growth may accelerate. Sustained fat loss with preserved lean mass.
Consider cycling off for 2-4 weeks to maintain pituitary sensitivity. Benefits plateau without periodic breaks.
What to Expect
Week 1-2: GH pulse onset, sleep and appetite changes. The GH spike hits within 15 to 30 minutes of subcutaneous injection. Most users notice improved sleep depth and vivid dreams within the first week of bedtime dosing. Appetite kicks up 20 to 30 minutes post-injection; it's less intense than GHRP-6 but noticeable. Transient tingling or dizziness for 5 to 15 minutes after injecting is common and harmless. Mild water retention starts building.
Weeks 3-4: Desensitization window, cycling is non-negotiable. Without 5-on/2-off scheduling, peak GH response drops roughly 38% by day five [1]. Users on continuous protocols notice a weaker post-injection response around this time. Those running the cycling schedule report more sustained effects. Recovery improvements become consistent: less DOMS, better training performance. Water retention stabilizes at a mild to moderate level.
Months 2-3: Body composition changes become visible. GH-mediated lipolysis and IGF-1 anabolic signaling accumulate over 8 to 12 weeks of consistent protocol adherence. Expect reduced abdominal fat, improved muscle fullness, and faster connective tissue recovery. Skin quality improves (elasticity, hydration). Hair and nail growth may speed up. Carpal tunnel symptoms can appear at higher dose frequencies; reduce dose immediately if tingling or grip weakness develops.
Month 3+ (off cycle): The compound clears within hours of the last injection (elimination half-life approximately 33 minutes). GHS-R1a receptor density recovers during the four-week off period. Sleep quality, recovery, and body composition benefits hold for four to six weeks post-cycle in most reports. Some regression occurs over eight to ten weeks without the protocol. Most users restart after four weeks off.
Detailed Timeline: Science vs Community
GH pulse detectable within 15-30 min of IV injection (Japan diagnostic data); SC GH peak at 30-60 min. GH promotes slow-wave sleep architecture.
Improved sleep depth and vivid dreams reported within the first week with bedtime dosing. Moderate appetite increase within 20-30 min post-injection. Mild tingling or dizziness shortly after injection is common.
GH attenuation reaches ~38% by day 5 of continuous daily dosing per PMID 9820615. Peak GH response declines measurably without cycling breaks. 5-on/2-off schedule attenuates this decline.
Users on continuous protocols note weaker post-injection response by week 3-4. Those running 5-on/2-off report more sustained effect. Recovery improvements become consistent: reduced DOMS, better training performance.
GH-mediated lipolysis and anabolic IGF-1 signaling accumulate over 8-12 weeks with consistent protocol adherence.
Visible reduction in abdominal fat, improved muscle fullness, and faster joint/connective tissue recovery. Skin quality improvements (elasticity, hydration) noted. Hair and nail growth may accelerate.
Short elimination half-life (~33 min) means compound clears within hours of last injection. GHS-R1a receptor density should recover within the 4-week off period.
Benefits (sleep quality, recovery, body composition) largely retained for 4-6 weeks post-cycle. Some regression in body composition over 8-10 weeks without protocol. Most users restart after 4 weeks off.
Pharmacokinetics
Source: Phase I pediatric PK study (Pihoker et al. 1998, PMID 9543135); t½β = 0.55 ± 0.14 h
Pharmacokinetics: Active Dose Over Time
t½ = ~33 minDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is GHRP-2 Legal?
GHRP-2 (pralmorelin) is classified as a research chemical in the United States. It has no FDA approval, and it is sold online labeled "for research purposes only."
Japan is the only country with a regulatory approval. The PMDA approved GHRP Kaken 100 (Kaken Pharmaceutical) in 2004 as a single-dose IV diagnostic agent for GH deficiency testing. The approved dose is 100 mcg IV bolus. It is not approved therapeutically in Japan or anywhere else.
GHRP-2 is not on the 503A bulks list (21 CFR 216.23), and FDA's 503A list (updated May 14, 2026) places it in Category 3, nominated without adequate support. FDA's Category 2 page (current as of April 22, 2026) lists GHRP-2 for injectable and nasal use under 503B, added September 29, 2023. FDA cites immunogenicity risk and reports of serious adverse events, though causality has not been established. GHRP-2 was not on the July 23-24, 2026 PCAC agenda.
WADA prohibits all GH secretagogues under the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes subject to anti-doping testing should not use GHRP-2.
This content is for informational and research purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any peptide.
Evidence grade: Approved outside the US (Peptide Evidence Gap, October 2026)
Who Should Consider GHRP-2
- Adults over 30 experiencing age-related GH decline (somatopause)
- Athletes and bodybuilders seeking enhanced recovery and lean mass
- Individuals on lean bulking protocols who benefit from moderate appetite increase
- Adults with poor sleep quality seeking improved deep sleep
- Patients undergoing GH stimulation testing for pituitary function assessment
Related Peptides
What Changed for GHRP-2
- Safety
Corrected Oct 17, 2026: the hexarelin cortisol study gives no ages in its abstract, so these pages say adults, not older adults, per Rahim 1999.
Before: In healthy older adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859) After: In adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859)
What this does not mean: The finding stands: 16 weeks of twice-daily hexarelin lowered the cortisol response and left the prolactin response unchanged. Only the description of the study group changed.
Also covers: GHRP-6, Hexarelin
Source: Clin Endocrinol 1999, The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 16, 2026: GHRP-2 raises prolactin by about as much as hexarelin at equal doses, not less, per Arvat 1997.
Before: The prolactin burden is lower than hexarelin but higher than ipamorelin After: The prolactin burden is similar to hexarelin's at equal doses (PMID 9285939) but higher than ipamorelin's
What this does not mean: GHRP-2 still raises prolactin, ACTH and cortisol. The comparison with ipamorelin is unchanged.
Source: Peptides 1997, Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 16, 2026: GHRP-2's cumulative cortisol burden claim is gone; 16 weeks of hexarelin in older adults lowered the cortisol response, per Rahim 1999.
Before: At three times daily advanced protocols, cumulative cortisol burden can become clinically relevant After: Long-term cortisol data for GHRP-2 are lacking; in older adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859)
What this does not mean: GHRP-2 still raises ACTH, cortisol and prolactin after each injection. Long-term cortisol data for GHRP-2 itself are lacking, and the AM cortisol check on the advanced protocol stays.
Source: Clin Endocrinol 1999, The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 16, 2026: the GHRP-2 + hexarelin warning no longer says hexarelin has the highest cortisol and prolactin rise of any GHRP, per Arvat 1997.
Before: Hexarelin already produces the highest cortisol and prolactin elevation of any GHRP After: At equal doses, hexarelin and GHRP-2 raise cortisol and prolactin by similar amounts (PMID 9285939)
What this does not mean: Stacking GHRP-2 with hexarelin is still advised against. Both bind GHS-R1a, add no documented GH benefit together, and raise cortisol and prolactin.
Source: Peptides 1997, Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Sep 24, 202616 Citations
References
- [1]Five-Day Daily SC GHRP-2 Causes GH Response Attenuation in Healthy Young Men (Nijland et al., Eur J Endocrinol 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Effects of GHRP-2 and Hexarelin on GH, Prolactin, ACTH and Cortisol Levels in Man (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Pharmacokinetics and Pharmacodynamics of Growth Hormone-Releasing Peptide-2: A Phase I Study in Children (Pihoker et al., J Clin Endocrinol Metab 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Growth Hormone Releasing Peptide-2 (GHRP-2), Like Ghrelin, Increases Food Intake in Healthy Men (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al., Clin Endocrinol 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]GH releasing peptides: structure and kinetics (Bowers, J Pediatr Endocrinol 1993) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [7]Ipamorelin, the first selective growth hormone secretagogue (Raun et al., Eur J Endocrinol 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [8]Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans (Arvat et al., J Endocrinol Invest 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Treatment Effects of Intranasal Growth Hormone Releasing Peptide-2 in Children with Short Stature (opens in a new tab)PubMed 9390009PubMed
- Growth Hormone-Releasing Peptides: Clinical and Basic Aspects (opens in a new tab)PubMed 8950613PubMed
- Sustained pulsatile GH secretion during 30-day continuous SC GHRP-2 infusion in older adults (J Clin Endocrinol Metab 2004) (opens in a new tab)PubMed 15126555PubMed
- Long-term oral GHRP-2 in GH-deficient children: appetite and weight outcomes (J Pediatr Endocrinol Metab 2003) (opens in a new tab)PubMed 14513874PubMed
- Eight-month GHRP-2 treatment with graded doses in GH-deficient children (J Clin Endocrinol Metab 1998) (opens in a new tab)PubMed 9661608PubMed
- GHRP-2 test for diagnosis of secondary adrenal failure (Endocr J 2016) (opens in a new tab)PubMed 27020037PubMed
- GHRP-2 test as a substitute for insulin tolerance test in hypopituitarism (Endocr J 2008) (opens in a new tab)PubMed 18493103PubMed
- Pralmorelin (GHRP-2 / KP-102): drug profile and Japan diagnostic approval (Drugs R D 2004) (opens in a new tab)PubMed 15230633PubMed
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is GHRP-2?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 100s. Community mentions on Reddit: Hundreds of threads on r/Peptides, r/steroids. Open r/Peptides (shared) (opens in a new tab).
200 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.